U055 Alopecia Areata Power Hour
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Alopecia areata is commonly encountered by dermatologists in clinical practice. While the diagnosis is typically straightforward, treatment can be challenging. This session will provide an overview of the diagnosis and management of alopecia areata, including recent progress in scientific understanding and therapeutics. Special focus will be paid to practical aspects of patient care such as navigating interactions with patients and families. We will review factors to consider when assessing disease severity and making treatment decisions and explore a range of available therapeutic options.
LEARNING OBJECTIVES
Recognize the psychosocial impact of alopecia areata and clinical factors that influence disease severity
Outline therapeutic options for alopecia areata
Describe the role of Janus kinase inhibitors for the treatment of alopecia areata
SCHEDULE
2:00 PM
Alopecia Areata Power Hour
Brittany Gareth Craiglow, MD, FAAD
SPEAKERS
Brittany Gareth Craiglow, MD, FAAD
SPEAKER DISCLOSURES
Brittany Gareth Craiglow, MD, FAAD
AbbVie – Speaker(Honoraria); Concert Pharmaceuticals – Consultant(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Speaker(Honoraria); EltaMD – Other(Honoraria); Incyte Corporation – Speaker(Honoraria); Pfizer Inc. – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Investigator(No Compensation Received), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Fees), Speaker(Honoraria); Roivant Sciences – Consultant(Fees); Sanofi Genzyme – Speaker(Honoraria);